Publications in collaboration with researchers from Hospital Arnau de Vilanova (18)

2024

  1. First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN

    Breast Cancer Research and Treatment, Vol. 206, Núm. 2, pp. 317-328

  2. Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study

    ESMO Open, Vol. 9, Núm. 10

  3. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer

    JAMA network open, Vol. 7, Núm. 4, pp. e247811

2021

  1. Early imaging and molecular changes with neoadjuvant bevacizumab in stage ii/iii breast cancer

    Cancers, Vol. 13, Núm. 14

  2. First-line osimertinib in patients with epidermal growth factor receptor–mutant non–small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met

    European Journal of Cancer, Vol. 159, pp. 174-181

2019

  1. A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

    Frontiers in Oncology, Vol. 9, Núm. APR

2018

  1. A risk-adapted approach to patients with stage i seminoma according to the status of rete testis: The fourth Spanish germ cell cancer group study

    Oncology (Switzerland), Vol. 95, Núm. 1, pp. 8-12

2017

  1. Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM “El Álamo III” retrospective study

    PLoS ONE, Vol. 12, Núm. 10

2016

  1. Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study

    BMC Cancer, Vol. 16, Núm. 1

  2. Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile

    Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428

2014

  1. Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer

    Oncology Research, Vol. 21, Núm. 4, pp. 181-191

  2. Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: The BRCA1-RAP80 Expression Customization (BREC) studies

    Annals of Oncology, Vol. 25, Núm. 11, pp. 2147-2155

2013

  1. SEOM clinical guidelines for the management of metastatic breast cancer 2013

    Clinical and Translational Oncology, Vol. 15, Núm. 12, pp. 1004-1010

2010

  1. Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients

    Lung Cancer, Vol. 68, Núm. 3, pp. 491-497

2006

  1. The place of targeted therapies in the management of non-small cell bronchial carcinoma: Molecular markers as predictors of tumor response and survival in lung cancer

    Revue des Maladies Respiratoires, Vol. 23, Núm. 5 C3

2003

  1. A multicenter phase II study of irinotecan in patients with advanced colorectal cancer previously treated with 5-fluorouracil

    Clinical Colorectal Cancer, Vol. 3, Núm. 3, pp. 174-179

  2. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: A Spanish Lung Cancer Group phase III randomized trial

    Journal of Clinical Oncology, Vol. 21, Núm. 17, pp. 3207-3213

  3. Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: A multicentre phase II study

    Lung Cancer, Vol. 39, Núm. 2, pp. 201-207